Bogart Wealth LLC Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Bogart Wealth LLC lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 38.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 92,768 shares of the medical research company's stock after purchasing an additional 25,657 shares during the period. Bogart Wealth LLC's holdings in Edwards Lifesciences were worth $6,868,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC lifted its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC lifted its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after buying an additional 166 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.7 %

EW stock traded down $0.52 during trading on Tuesday, reaching $75.67. The stock had a trading volume of 4,937,936 shares, compared to its average volume of 4,574,817. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company's 50 day moving average is $72.78 and its two-hundred day moving average is $69.68. The company has a market capitalization of $44.63 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on EW. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and a consensus target price of $79.95.

Insider Buying and Selling

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company's stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,489 shares of company stock worth $2,002,829. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.